She'll succeed Juan Ramon Alaix, 68, who is retiring. Alaix, named CEO in July 2012, will advise the company on the transition until the end of 2020.
Peck, 48, is currently executive vice president and group president of U.S. operations, business development and strategy. She's been in Zoetis's executive leadership since the company was founded in 2012.
At Zoetis, she also managed manufacturing and supply and new-product marketing and market research, among other functions. Her background includes a tenure as Pfizer's executive vice president of worldwide business development and innovation.
For the first six months of 2019, Zoetis earned $1.41 a share, down from $1.51 in the year-earlier first half. Revenue rose almost 8% to $3 billion.
The Parsippany, N.J., company produces medicines, vaccines and diagnostics, along with biodevices, genetic tests and services. Its customer base includes veterinarians, livestock producers and people who raise and care for farm and companion animals.
Zoetis stock is trading on Thursday up 1.4% at $124.02, near its 52-week high of $130.08, set early last month.
Save 57% During Our Fall Sale. Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor. Click here to sign up and save!